DUBLIN–(BUSINESS WIRE)–The “Global
Smoking Cessation Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.
Smoking Cessation Pipeline Highlights – 2019, provides most
up-to-date information on key pipeline products in the global Smoking
Cessation market. It covers emerging therapies for Smoking Cessation in
active clinical development stages including early and late stage
clinical trials. The pipeline data presented in this report helps
executives in tracking competition, identifying partners, evaluating
opportunities, formulating business development strategies, and
executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Smoking Cessation pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Smoking Cessation pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.
Company:
The report provides Smoking Cessation pipeline products by the company.
Short-term Launch Highlights:
Find out which Smoking Cessation pipeline products will be launched in
the US and Ex-US to 2024.
Summary:
- Smoking Cessation phase 3 clinical trial pipeline products
- Smoking Cessation phase 2 clinical trial pipeline products
- Smoking Cessation phase 1 clinical trial pipeline products
- Smoking Cessation preclinical research pipeline products
- Smoking Cessation discovery stage pipeline products
- Smoking Cessation pipeline products short-term launch highlights
Key Topics Covered:
1. Smoking Cessation Pipeline by Stages
2. Smoking Cessation Phase 3 Clinical Trial Insights
3. Smoking Cessation Phase 2 Clinical Trial Insights
4. Smoking Cessation Phase 1 Clinical Trial Insights
5. Smoking Cessation Preclinical Research Insights
6. Smoking Cessation Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/ur885v
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Over
the Counter (OTC) Drugs, Clinical
Trials, Addiction
Disorders Drugs